A PHP Error was encountered

Severity: Warning

Message: Creating default object from empty value

Filename: models/publicacao_item.php

Line Number: 20

Pattern Electroretinography in Age-Related Macular Degeneration... » Isaúde
  Pesquisar Publicações Científicas  
  Especialidade: carregando especialidades...  Carregando...
Nome da revista:   Volume:   Número:
Archives of ophthalmology
2011-05-09 19:51:34

Pattern Electroretinography in Age-Related Macular Degeneration [Clinical Sciences]

Assunto: Aging/ Geriatrics, Ophthalmology, Ophthalmological Disorders, Choroidal Neovascularization, Macular Degeneration, Retinal/ Chorioretinal Disorders, Randomized Controlled Trial, Drug Therapy, Adverse Effects

Descrição: Objective  To determine whether prolonged vascular endothelial growth factor inhibition is toxic to the retina by using pattern electroretinographic imaging in participants with neovascular age-related macular degeneration (AMD).Methods  We performed a prospective, single-arm clinical trial of 17 eyes in 17 treatment-naive participants with subfoveal choroidal neovascularization from AMD. On-label intravitreous ranibizumab was injected monthly for 6 months. Then pattern electroretinographic imaging was performed before and at 1 month, 3 months, and 6 months after first treatment, and results were interpreted by a trained reader masked to the clinical data. The primary outcome measure was the change in pattern electroretinographic imaging (positive wave peaking at 50 milliseconds [P50] and negative wave peaking at 95 milliseconds [N95] values) from baseline at 6 months. The secondary outcome measure was the change in visual acuity at 6 months.Results  The mean participant age was 79.6 years (range, 69.5-90.4 years). At baseline, mean (SD) P50 and N95 amplitudes were 1.3 (0.69) µV and 1.5 (0.71) µV, respectively. By 6 months, no decrease in P50 or N95 amplitudes from baseline was observed (1.4 [0.47] µV, P = .46; and 1.8 [0.96] µV, P = .14, respectively). Mean visual acuity before treatment was 20/85 with improvement to a mean of 20/55 (P = .004) at 6 months.Conclusions  This study found no decrease in P50 and N95 amplitudes in participants treated with ranibizumab for neovascular AMD. These findings indicate that vascular endothelial growth factor inhibition with monthly injections of ranibizumab for 6 months likely does not lead to retinal damage.Trial Registration  clinicaltrials.gov Identifier: NCT00500344

Identificador: i
Editorial: American Medical Association
Seção: Clinical Sciences
Número: 5
Volume: 129
Página: 580 a 584
Autor: Sheybani, A., Brantley, M. A., Apte, R. S.


Mais informações

  • Twitter iSaúde
publicidade
Jornal Informe Saúde

Indique o portal
Fechar [X]
  • Você está indicando a notícia: http://www.isaude.net
  • Para que seu amigo(a) receba esta indicação preencha os dados abaixo:

RSS notícias do portal  iSaúde.net
Receba o newsletter do portal  iSaúde.net
Indique o portal iSaúde.net
Notícias do  iSaúde.net em seu blog ou site.
Receba notícias com assunto de seu interesse.
© 2000-2011 www.isaude.net Todos os direitos reservados.